Literature DB >> 3974685

Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria.

E R Yendt, M Cohanim.   

Abstract

We measured urinary oxalate and glycolate excretion before and during pyridoxine administration (2 to 200 mg per day) in four patients with primary hyperoxaluria. In two patients with type I primary hyperoxaluria, urinary oxalate and glycolate excretion fell markedly in response to a physiologic dose of pyridoxine of 2 mg per day and became completely normal when the dose was increased to 25 mg per day. In the other two patients, who had a different type of primary hyperoxaluria (normal urinary glycolate excretion), there was no response to 2 mg of pyridoxine per day. In one of these patients, doses of 25 and 50 mg per day were also ineffective, but a moderate reduction in oxalate excretion took place with 200 mg per day; in the other patient there was a moderate reduction in oxalate excretion with 25 mg of pyridoxine per day. Our findings suggest that the degree of hyperoxaluria in this disorder may be only slight or moderate if the patient has been ingesting a pyridoxine-rich diet or multivitamin tablets containing small amounts of pyridoxine. Our results also suggest that smaller doses of pyridoxine than those heretofore employed should be tried in patients with primary hyperoxaluria.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974685     DOI: 10.1056/NEJM198504113121504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  17 in total

Review 1.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

Review 2.  [Evidence-based pharmacological metaphylaxis of stone disease].

Authors:  M Straub; R E Hautmann
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

Review 3.  Management of primary hyperoxaluria: efficacy of oral citrate administration.

Authors:  E Leumann; B Hoppe; T Neuhaus
Journal:  Pediatr Nephrol       Date:  1993-04       Impact factor: 3.714

4.  Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.

Authors:  Heike Hoyer-Kuhn; Sina Kohbrok; Ruth Volland; Jeremy Franklin; Barbara Hero; Bodo B Beck; Bernd Hoppe
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-02       Impact factor: 8.237

5.  [Type I oxalosis in childhood--studies within the scope of terminal renal failure in the child].

Authors:  M Frosch; E Kuwertz-Bröking; M Bulla; D B von Bassewitz; D B Leusmann
Journal:  Klin Wochenschr       Date:  1989-11-17

Review 6.  Urolithiasis in children: current medical management.

Authors:  J Laufer; H Boichis
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

7.  Control of hyperoxaluria with large doses of pyridoxine in patients with kidney stones.

Authors:  A Mitwalli; A Ayiomamitis; L Grass; D G Oreopoulos
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

8.  A novel mutation in the AGXT gene causing primary hyperoxaluria type I: genotype-phenotype correlation.

Authors:  Saoussen M'Dimegh; Cécile Aquaviva-Bourdain; Asma Omezzine; Ibtihel M'Barek; Geneviéve Souche; Dorsaf Zellama; Kamel Abidi; Abdelattif Achour; Tahar Gargah; Saoussen Abroug; Ali Bouslama
Journal:  J Genet       Date:  2016-09       Impact factor: 1.166

9.  New aspects of infantile oxalosis.

Authors:  E P Leumann; A Niederwieser; A Fanconi
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

10.  A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria.

Authors:  Bernd Hoppe; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2003-08-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.